Close Menu

NEW YORK (GenomeWeb) – CareDx and French medical technology firm Cibiltech announced today that they are partnering to commercialize Predigraft, a data analysis tool that provides an early prediction of an individual's risk of allograft rejection and transplant loss.

Under the terms of the agreement, CareDx will hold the exclusive rights to commercialize Predigraft in the US and will also become a minority equity owner of Cibiltech. The companies have also agreed to collaborate to advance the development of artificial intelligence in transplant care.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.